Emergency Use Authorization for COVID-19 antibody

Coronavirus Vaccines

The U.S. Food and Drug Administration on Saturday issued emergency use authorization for Regeneron Pharmaceuticals Inc’s COVID-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.

The FDA said the monoclonal antibodies, casirivimab and imdevimab, should be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19.

This includes those who are 65 years of age or older or who have certain chronic medical conditions.

The treatment is part of a class of drugs known as monoclonal antibodies, which are manufactured copies of antibodies created by the human body to fight infections.

Read the full article here.

Like this article?

Facebook
Twitter
LinkedIn
Pinterest

More Articles

ICD-10

ICD-10 Prep Timing is Crucial

Providers are waking up to the need for ICD-10 education, but “one of worst mistakes theycould make would be to get the training too early in the year.

Vitamin D Deficiency

Chronic Pain Linked To Vitamin D Deficiency In Men

Vitamin D deficiency has been linked to a number of health issues. And now, a new study to be presented at a conference run by the British Society for Rheumatology suggests that low levels of vitamin D in the body are linked to chronic widespread pain.